Fig. 3.

Consistent treatment effect of empagliflozin vs. placebo in those with and without metabolic syndrome at baseline. *Excluding fatal stroke. Cox models include terms for baseline age, sex, HbA1c, eGFR, geographical region, treatment, MetS at baseline and treatment*MetS at baseline interaction. p-values for treatment-by-subgroup interaction were obtained from tests of homogeneity of treatment group differences among subgroups with no adjustment for multiple testing. CV cardiovascular, HHF hospitalization for heart failure, MetS metabolic syndrome, py patient-years